首页> 外文OA文献 >Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques▿
【2h】

Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques▿

机译:质粒DNA疫苗设计和体内电穿孔对猕猴产生的疫苗特异性免疫反应的影响▿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since human immunodeficiency virus (HIV)-specific cell-mediated immune (CMI) responses are critical in the early control and resolution of HIV infection and correlate with postchallenge outcomes in rhesus macaque challenge experiments, we sought to identify a plasmid DNA (pDNA) vaccine design capable of eliciting robust and balanced CMI responses to multiple HIV type 1 (HIV-1)-derived antigens for further development. Previously, a number of two-, three-, and four-vector pDNA vaccine designs were identified as capable of eliciting HIV-1 antigen-specific CMI responses in mice (M. A. Egan et al., Vaccine 24:4510-4523, 2006). We then sought to further characterize the relative immunogenicities of these two-, three-, and four-vector pDNA vaccine designs in nonhuman primates and to determine the extent to which in vivo electroporation (EP) could improve the resulting immune responses. The results indicated that a two-vector pDNA vaccine design elicited the most robust and balanced CMI response. In addition, vaccination in combination with in vivo EP led to a more rapid onset and enhanced vaccine-specific immune responses. In macaques immunized in combination with in vivo EP, we observed a 10- to 40-fold increase in HIV-specific enzyme-linked immunospot assay responses compared to those for macaques receiving a 5-fold higher dose of vaccine without in vivo EP. This increase in CMI responses translates to an apparent 50- to 200-fold increase in pDNA vaccine potency. Importantly, in vivo EP enhanced the immune response against the less immunogenic antigens, resulting in a more balanced immune response. In addition, in vivo EP resulted in an approximate 2.5-log10 increase in antibody responses. The results further indicated that in vivo EP was associated with a significant reduction in pDNA persistence and did not result in an increase in pDNA associated with high-molecular-weight DNA relative to macaques receiving the pDNA without EP. Collectively, these results have important implications for the design and development of an efficacious vaccine for the prevention of HIV-1 infection.
机译:由于人类免疫缺陷病毒(HIV)特异的细胞介导的免疫(CMI)应答对于早期控制和解决HIV感染至关重要,并且与猕猴攻击实验中的攻击后结果相关,因此我们寻求鉴定质粒DNA(pDNA)疫苗该设计能够引发对多种HIV 1型(HIV-1)衍生抗原的稳健而平衡的CMI反应,以进一步开发。以前,已经确定了许多两种,三种和四种载体的pDNA疫苗设计能够在小鼠中引发HIV-1抗原特异性CMI反应(MA Egan等人,Vaccine 24:4510-4523,2006) 。然后,我们试图进一步表征这两种,三种和四种载体pDNA疫苗设计在非人类灵长类动物中的相对免疫原性,并确定体内电穿孔(EP)可以改善所得免疫反应的程度。结果表明,两载体pDNA疫苗设计引起了最强劲和平衡的CMI反应。此外,疫苗与体内EP的结合导致更快速的发作和增强的疫苗特异性免疫反应。与接受体内EP组合免疫的猕猴相比,与未接受体内EP的疫苗接种高5倍的猕猴相比,HIV特异性酶联免疫斑点测定反应增加了10至40倍。 CMI反应的这种增加转化为pDNA疫苗效力的明显增加50到200倍。重要的是,体内EP增强了针对免疫原性较低的抗原的免疫反应,从而导致了更加平衡的免疫反应。另外,体内EP导致抗体应答大约增加2.5-log10。结果进一步表明,与不接受EP的pDNA的猕猴相比,体内EP与pDNA的持久性显着降低有关并且与高分子量DNA相关的pDNA没有增加。总体而言,这些结果对预防和预防HIV-1感染的有效疫苗的设计和开发具有重要意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号